Geron Newsroom

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireDec 20 05:30

Express News | Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

BreakingsDec 20 05:30

Geron Corporation (NASDAQ:GERN) Is a Favorite Amongst Institutional Investors Who Own 72%

Yahoo FinanceDec 19 02:19

Geron Announces Positive CHMP Opinion for Rytelo

Yahoo FinanceDec 14 19:40

Needham Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6

Futu NewsDec 13 22:31 · Ratings

Sector Update: Health Care Stocks Steady Premarket Friday

MT NewswiresDec 13 22:17

Needham Reiterates Buy on Geron, Maintains $6 Price Target

BenzingaDec 13 22:05 · Ratings

Buy Rating on Geron Driven by EU Approval Prospects and Strategic Commercialization of Rytelo

TipRanksDec 13 22:05 · Ratings

Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk...

BenzingaDec 13 19:38

Express News | Geron Announces Positive Chmp Opinion for Rytelo™ (Imetelstat) for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk Mds

BreakingsDec 13 19:36

Stifel Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $8

Futu NewsDec 11 21:31 · Ratings

Geron (GERN) Gets a Buy From Stifel Nicolaus

TipRanksDec 11 20:45 · Ratings

TD Cowen Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $10

Futu NewsDec 11 19:31 · Ratings

Geron (GERN) Receives a Buy From TD Cowen

TipRanksDec 11 18:48 · Ratings

Is Geron Corporation (GERN) the Best NASDAQ Penny Stock to Buy Right Now?

Yahoo FinanceDec 11 15:15

Geron Announces Phase 1 Findings From Two-Part IMproveMF Study Suggesting Tolerability Of RYTELO In Combination With Ruxolitinib As Frontline Therapy In Patients With Myelofibrosis Presented At ASH; In The Dose Escalation Part 1 Of The Study, No...

BenzingaDec 10 22:09

Express News | Geron Announces New Imerge Analyses Presented at Ash Suggesting Clinical Activity of Rytelo™ (Imetelstat) in Patients With Lower-Risk Mds Regardless of Type or Number of Prior Therapies

BreakingsDec 10 22:00

Express News | Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis

BreakingsDec 10 22:00

Geron Analyst Ratings

BenzingaDec 10 20:17 · Ratings

H.C. Wainwright Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9

Futu NewsDec 10 19:31 · Ratings